New Study Confirms Statins can Raise Increase Risk of Type 2 Diabetes

by Barbara Hewitt on April 24, 2015

Statins, a popular drug used to lessen the chance of heart attacks and strokes, can actually increase the risk of developing type 2 diabetes, a new study has confirmed.

Scientists from Finland say in a new research paper that the use of statins is associated with a 46% increase in the risk of developing diabetes, even after adjustment for confounding factors.

diabetesDRUGSPrevious studies have suggested an increased risk at varying levels of developing diabetes associated with statin use. However, these studies have had limitations such as being selective, especially in statin trials which have included participants at high risk of cardiovascular disease.

Therefore, the risk of diabetes in clinical trials is likely to differ from that in the general population. Very often in previous studies the diagnosis of diabetes has been based on self-reported diabetes or fasting glucose measurement, leading to an underestimation of the actual numbers of incident diabetes cases.

In this new study, Professor Markku Laakso of the Institute of Clinical Medicine at the University of Eastern Finland and Kuopio University Hospital, Finland, investigated the effects of statin treatment on the risk of type 2 diabetes and deterioration of blood sugar control.

They examined details of 8,749 non-diabetic men aged 45 to 73 in a six year follow-up of the population based Metabolic Syndrome in Men (METSIM) study, based in Kuopio, Finland. They also examined the mechanisms of statin induced diabetes by evaluating changes in insulin resistance and insulin secretion.

New diabetes was diagnosed in 625 men with either an oral glucose tolerance test (OGTT), an HbA1c level of 6.5% or higher, or anti-diabetic medication started during the follow-up, and insulin sensitivity and secretion were evaluated.

The researchers found that, after the results were adjusted for age, body mass index (BMI), waist circumference, physical activity, smoking, alcohol intake, family history of diabetes, and beta-blocker and diuretic treatment, patients treated with statins were 46% more likely to develop diabetes than those not treated with statins.

The risk was dose-dependent for simvastatin and atorvastatin. Statin treatment significantly increased 2-h glucose (2hPG) at follow-up, with a nominally significant increase in fasting glucose (FPG). Insulin sensitivity was decreased by 24% and insulin secretion by 12% in individuals on statin treatment.

Furthermore, decreases in insulin sensitivity and insulin secretion were dose-dependent for simvastatin and atorvastatin. And, after adjustment for all the confounders mentioned above, high-dose simvastatin was associated with a 44% increased risk of developing diabetes, while for low-dose simvastatin the increased risk was 28% and for high-dose atorvastatin the increased risk was 37%. Overall, 29% of participants were taking simvastatin, while 53% were taking atorvastatin.

‘The association of statin use with increased risk of developing diabetes is most likely directly related to statins decreasing both insulin sensitivity and secretion,’ the study says and also points out that while the size of the study makes their conclusions reliable, the study sample was Caucasian men, so the applicability to women or people of other ethnic origin cannot be confirmed without further research.

‘Statin therapy was associated with a 46% increased risk of type 2 diabetes after adjustment for confounding factors, suggesting a higher risk of diabetes in the general population than previously reported,’ it concludes.

 


The opinions expressed in this article do not necessarily reflect the views of the DiabetesForum.com Community and should not be interpreted as medical advice. Please see your doctor before making any changes to your diabetes management plan.

{ 0 comments… add one now }

Leave a Comment

Previous post:

Next post: